iBio (IBIO) Return on Capital Employed (2011 - 2026)
iBio's (IBIO) quarterly Return on Capital Employed came in at 42.21% in Q1 2026, up 6986.0% year-on-year from 0.6% in Q1 2025, and up 3.28% on a QoQ basis from 43.64% in Q4 2025.
iBio (IBIO) Return on Capital Employed (2011 - 2026) Analysis & Trends
iBio (IBIO) has 16 years of Return on Capital Employed data on file, last reported at 42.21% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 6986.0% year-over-year to 42.21% in Q1 2026; TTM through Mar 2026 was 42.21%, a 6986.0% increase from a year earlier, with the FY2025 full-year figure at 93.7%, down 4026.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 42.21%, up from 43.64% in the prior quarter.
- Over the last five years, Return on Capital Employed for IBIO reached as high as 25.47% in Q1 2022 and fell as low as 145.02% in Q4 2023.
- Historically, Return on Capital Employed has averaged 84.31% across 5 years, with a median of 84.57% in 2024.
- Across the five-year window, Return on Capital Employed slumped 10945 bps in 2023 and surged 9512 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 87.73% in 2022, then sank by 65 bps to 145.02% in 2023, then jumped by 42 bps to 84.57% in 2024, then soared by 48 bps to 43.64% in 2025, then gained by 3 bps to 42.21% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 42.21% in Q1 2026, 43.64% in Q4 2025, and 54.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -42.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.21% |
| Dec 31, 2025 | -43.64% |
| Sep 30, 2025 | -54.35% |
| Jun 30, 2025 | -123.70% |
| Mar 31, 2025 | -112.06% |
| Dec 31, 2024 | -84.57% |
| Sep 30, 2024 | -67.53% |
| Jun 30, 2024 | -46.72% |
| Mar 31, 2024 | -88.04% |
| Dec 31, 2023 | -145.02% |
| Sep 30, 2023 | -143.10% |
| Jun 30, 2023 | -141.84% |
| Mar 31, 2023 | -134.91% |
| Dec 31, 2022 | -87.73% |
| Sep 30, 2022 | -53.70% |
| Jun 30, 2022 | -38.59% |
| Mar 31, 2022 | -25.47% |
| Dec 31, 2021 | -22.96% |
| Sep 30, 2021 | -21.43% |
| Jun 30, 2021 | -22.51% |